CDK4 and metastatic neoplasm: However, treatment resistance inevitably ensues, and the optimal management after prior CDK4/6i plus ET continues to be refined, especially with the increasing use of adjuvant CDK4/6i8, as well as adjuvant poly ADP-ribose polymerase inhibitors (PARPi)9, changing the profile of patients with recurrent metastatic disease.